Zosano Appoints Industry Veteran, Kathy McGee, to its Board of Directors
May 25 2021 - 3:05PM
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage
biopharmaceutical company, today announced the appointment of Kathy
McGee, an accomplished biopharmaceutical executive, to its board of
directors. Ms. McGee brings experience from a broad range of
leadership roles across operations, strategic planning,
manufacturing and supply chain management, quality and regulatory
affairs and new product development.
“Kathy is an exceptional addition to the board, bringing deep
experience across many functional areas, and we are thrilled to
have her join our board,” said Steven Lo, president and chief
executive officer of Zosano. “As we work to initiate the
pharmacokinetic (PK) study required to resubmit our new drug
application for Qtrypta™, we continue to prepare for resubmission,
pending receipt of positive PK study data and commercialization. We
look forward to Kathy’s guidance as we navigate towards the
commercial marketplace.”
Ms. McGee added, “I’m pleased to join the board of Zosano at
this exciting time in the company’s evolution. If approved by the
FDA, Qtrypta would represent a therapeutic treatment option for
patients with acute migraines as the first and only transdermal
microneedle patch for a patient population where fast onset of
action is a key attribute, and where nausea sometimes becomes an
impediment to oral therapy. I look forward to working closely with
Zosano management to prepare for a potential commercial
launch.”
Ms. McGee is currently chief operating officer of AVITA MEDICAL,
where she is responsible for manufacturing operations, facilities
and engineering, supply chain, program management, new product
development, information technology and quality and regulatory
affairs. Prior to AVITA, she was president of CnA Consulting Group,
a life science consulting firm specializing in helping companies
with strategic planning and analysis, mergers and acquisitions
strategy, chemistry, manufacturing and controls planning,
pre-approval readiness, technical operations and supply chain
logistics, compliance and regulatory management. Earlier in her
career, she served in executive roles at Shire Regenerative
Medicine, where she led West Coast Operations and Advanced
Biohealing, Inc. where she was a general manager of the
organization. Ms. McGee has a Master of Arts degree from Webster
University, St. Louis and a Bachelor of Science in Chemistry and
Mathematics from University College, Galway.
About Zosano PharmaZosano Pharma Corporation is
a clinical-stage biopharmaceutical company focused on developing
products where rapid administration of approved molecules with
established safety and efficacy profiles may provide substantial
benefit to patients, in markets where patients remain underserved
by existing therapies. The company’s transdermal microneedle system
technology consists of titanium microneedles coated with drug that
are designed to enable rapid systemic administration of
therapeutics to patients. Zosano’s lead product candidate is
Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan
designed to be delivered via its transdermal microneedle system
technology, as an acute treatment for migraine. Learn more at
www.zosanopharma.com.
Forward-Looking StatementsThis press release
contains forward-looking statements. All statements other than
statements of historical facts contained herein are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, including, but
not limited to, statements regarding the company’s plans for the PK
study, the company’s plans for resubmission of the company’s
Qtrypta NDA to the FDA, the potential benefits and commercial
launch of Qtrypta for patients and other future events and
expectations described in this press release. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "approximately" or the
negative of those words or other comparable words to be uncertain
and forward-looking. These statements are subject to risks and
uncertainties that are difficult to predict, and actual outcomes
may differ materially. These include risks and uncertainties,
without limitation, associated with the company’s ability to obtain
additional cash resources to continue operations, the process of
discovering, developing and commercializing products that are safe
and effective for use as human therapeutics, risks inherent in the
effort to build a business around such products and other risks and
uncertainties described under the heading "Risk Factors" in the
company's most recent annual report on Form 10-K and quarterly
reports on Form 10-Q. Although Zosano believes that the
expectations reflected in these forward-looking statements are
reasonable, Zosano cannot in any way guarantee that the future
results, level of activity, performance or events and circumstances
reflected in forward-looking statements will be achieved or occur.
All forward-looking statements are based on information currently
available to Zosano and Zosano assumes no obligation to update any
such forward-looking statements.
Zosano Contacts:Christine MatthewsChief
Financial Officer510-745-1200
Zosano PR:Sylvia Wheeler or Alexandra
Santosswheeler@wheelhouselsa.com or asantos@wheelhouselsa.com
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Apr 2024 to May 2024
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From May 2023 to May 2024